References in periodicals archive ?
David Schilansky, CFO at DBV Technologies SA, said, 'we are excited about being more visible in the US and having direct access to US investors through our NASDAQ listing.
Pierre-Henri Benhamou, Chairman and CEO of DBV Technologies, said: "The strategic manufacturing agreement with Sanofi is an important step for DBV in the light of Viaskin's late-stage development and potentially fast-coming commercialization.
Pierre-Henri Benhamou, Chairman & CEO of DBV Technologies, commented: "DBV has dramatically evolved in 2012, with the IPO providing sufficient financing for our corporate goals.
Cumulated placements managed by Bryan, Garnier & Co in healthcare exceeded 1b[euro] over the past 24 months including 3 Nasdaq IPOs (Galapagos, DBV Technologies and LDR Holding).
Henry Mooney, business development manager at DBV, said: "Forming this partnership with NEL allows us to extend the range of opportunities we can offer to new and existing businesses.
Pierre-Henri Benhamou, Chairman and CEO of DBV Technologies, said: "We are very proud to announce this new collaboration with INRA and especially the VIM unit.
DBV Technologies,(Euronext: DBV - ISIN: FR0010417345), creator of Viaskin[R], a new standard in the treatment of allergies, announced today its financial calendar for 2013*.
DBV tackles a high unmet medical need: HDM allergy in young children recognized a key risk factor for asthma in children.
The CIML is recognized for its advances in the knowledge of immune system cells involved in allergic reactions, a key stage in understanding the specific immunotherapy method using Viaskin[R] invented by DBV Technologies
Moments ago, Analysts Review released new research updates concerning several important developing situations including Clovis Oncology (NASDAQ: CLVS), DBV Technologies (NASDAQ: DBVT), Cleveland BioLabs (NASDAQ: CBLI), Arrowhead Research (NASDAQ: ARWR), and Athenahealth (NASDAQ: ATHN).
V Circassia CMC Biologics Cobra Biologics Colby Pharmaceutical Cook Pharmica Corden Pharma Covance Crucell CSL Biologicals Cytos Biotechnology Cytovance Biologics Daiichi Sankyo Dalian Hissen Bio-Pharm DBV Technologies Dendreon DSM Biologics Dynport Vaccine EMD Serono Emergent BioSolutions Endocyte Etubics Eurogentec Biologics FiberCell Frazier Healthcare Fujifilm Diosynth Biotechnologies Galena Gcon GE Healthcare Life Sciences GE Wave Biotech GeneCure Biotechnologies Genetic Immunity Genocea Biosciences GenPhar GenVec GeoVax GlaxoSmithKline Biologicals Gliknik Globelmmune Goodwin Biotechnology Inc.
DBV Technologies (Paris:DBV) (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin[R], a new standard in the treatment of allergy, announced today its first nine months topline and its clinical progress as well as the international registration of the EPIT[R] (Epicutaneous Immunotherapy) brand.
Encyclopedia browser ?
Full browser ?
- DBUF Transmit FIFO Overflow